Literature DB >> 30190909

What is new in melanoma after European Cancer Congress 2017?

Piotr Rutkowski1.   

Abstract

Entities:  

Keywords:  BRAF inhibitor; MEK inhibitor; adjuvant; anti-CTLA-4; anti-PD-1; immunotherapy; melanoma; metastases; neoadjuvant

Year:  2017        PMID： 30190909      PMCID： PMC6094666          DOI： 10.2217/mmt-2017-0004

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  6 in total

1.  Introduction to the special issue of European Journal of Surgical Oncology: New roads in melanoma management.

Authors:  P Rutkowski
Journal:  Eur J Surg Oncol       Date:  2016-12-14       Impact factor: 4.424

2.  Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.

Authors:  Corneel Coens; Stefan Suciu; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Celeste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Andrew Bottomley; Srividya Kotapati; Veerle de Pril; Alessandro Testori; Alexander M M Eggermont
Journal:  Lancet Oncol       Date:  2017-02-03       Impact factor: 41.316

3.  Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

Authors:  Sandra P D'Angelo; James Larkin; Jeffrey A Sosman; Celeste Lebbé; Benjamin Brady; Bart Neyns; Henrik Schmidt; Jessica C Hassel; F Stephen Hodi; Paul Lorigan; Kerry J Savage; Wilson H Miller; Peter Mohr; Ivan Marquez-Rodas; Julie Charles; Martin Kaatz; Mario Sznol; Jeffrey S Weber; Alexander N Shoushtari; Mary Ruisi; Joel Jiang; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2016-11-07       Impact factor: 44.544

4.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

Authors:  Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Lars Bastholt; Laurent Mortier; Luc Thomas; Saad Tahir; Axel Hauschild; Jessica C Hassel; F Stephen Hodi; Corina Taitt; Veerle de Pril; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

5.  Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.

Authors:  Claus Garbe; Ketty Peris; Axel Hauschild; Philippe Saiag; Mark Middleton; Lars Bastholt; Jean-Jacques Grob; Josep Malvehy; Julia Newton-Bishop; Alexander J Stratigos; Hubert Pehamberger; Alexander M Eggermont
Journal:  Eur J Cancer       Date:  2016-06-29       Impact factor: 9.162

Review 6.  Survival of patients with advanced metastatic melanoma: The impact of novel therapies.

Authors:  Selma Ugurel; Joachim Röhmel; Paolo A Ascierto; Keith T Flaherty; Jean Jacques Grob; Axel Hauschild; James Larkin; Georgina V Long; Paul Lorigan; Grant A McArthur; Antoni Ribas; Caroline Robert; Dirk Schadendorf; Claus Garbe
Journal:  Eur J Cancer       Date:  2015-12-17       Impact factor: 9.162
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.